Compare Recursion Pharmaceuticals Inc (RXRX) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vital Farms Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $4.27 (market cap $2.14B), while Vital Farms Inc trades at $9.36 (market cap $405.27M). The key difference: Recursion Pharmaceuticals Inc is far larger — about 5.3× Vital Farms Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Vital Farms Inc for 14 Days on average.
| RXRX | VITL | |
|---|---|---|
Market Cap | $2.14B | $405.27M |
Volume | 30,789,535 | 1,810,837 |
Sector | Health | Consumer Staples |
52-Week High | $6.79 | $43.68 |
52-Week Low | $2.84 | $8.28 |
Typical Hold Time | 22 Days | 14 Days |
Enterprise Value | $1.66B | $492.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Vital Farms (VITL) trades at $9.45, up 2.27% today, amid a challenging fundamental backdrop. The stock exhibits a bearish technical trend, with recent earnings showing significant pressure on profitability. Revenue for 2025 was $759.44M with a net income of $66.28M, but 2026 projections indicate a sharp decline in net income to near breakeven. Recent news highlights strategic review discussions and institutional investment activity, contributing to volatile price action.
The outlook is mixed; analyst consensus is bullish with a $13.11 price target, but near-term risks from egg pricing pressure and weak profitability metrics pose challenges. Investment opportunity hinges on successful execution of strategic options and margin recovery, while downside risks include sustained industry oversupply and cash flow constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
